In vitro studies reported in NEJM show that Pfizer/Moderna vaccines were still able to neutralize variant B.1.351 from South Africa despite reduction in neutralizing antibodies. Authors’ opinion is that vaccine remains efficacious. More to follow.

Dr. Barry Dworkin

Medical Mythbusting Commentary for February 18, 2021

In vitro studies reported in the NEJM show that Pfizer/Moderna vaccines were still able to neutralize the variant B.1.351 from South Africa despite reduction in neutralizing antibodies. Authors' opinion is that vaccine remains efficacious. More to follow. Play Now | Play in Popup | Download

Source:
Pfizer says South African variant could notably cut down vaccine protection

Reference:
Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

Related posts:

  1. South African coronavirus variant being studied to determine if it is more vaccine resistant.
  2. Ottawa Public Health reports first case of variant from South Africa. Will this intensify restrictions or will measures be relaxed next week by Ontario Government?
  3. First case of South African variant confirmed in Ontario’s Peel Region. Person had no history of travel. Dominance by more vaccine-resistant virus helped in part by slow vaccine rollout, incomplete public health measures and virus response to same.
  4. Israeli study offers more evidence of Pfizer vaccine efficacy with 94% drop in symptomatic cases and 92% decrease in severe illness in people aged 55 and older.—- Restriction-easing plan in Ontario risks Yo-Yo effect once again.
Bitnami